Milwaukee, WINCT06708845Now EnrollingIRB Ready

Lupus Nephritis Clinical Trial in Milwaukee, WI

Access cutting-edge lupus nephritis treatment through this phase 1 clinical trial at a research site in Milwaukee. Study-provided care at no cost to qualified participants.

Sponsored by Miltenyi Biomedicine GmbH

Quick Self-Assessment

See if you qualify for this Milwaukee location

Preparing your pre-screening questions…

Expert Care in Milwaukee

Access lupus nephritis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related lupus nephritis treatment provided free

Apply for This Milwaukee Location

Check if you qualify for this lupus nephritis clinical trial in Milwaukee, WI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Milwaukee

    Convenient for WI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Milwaukee site if eligible
  4. 4Begin participation

About This Lupus Nephritis Study in Milwaukee

AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.

Sponsor: Miltenyi Biomedicine GmbH

Who Can Participate

Exclusion Criteria

Across All Cohorts Inclusion Criteria: •Confirmed diagnosis of autoimmune disease (SLE-Non-renal, SLE-LN, SSc/ dcSSc) Exclusion Criteria:
Prior gene therapy treatment
Active malignancy within past 5 years
Significant active fungal or bacterial infection
History or presence of CNS lupus or other CNS disease
eGFR \< 45 mL/min/1.73 m\^2
Total bilirubin outside the normal range (unless congenital hyperbilirubinemia such as Gilbert syndrome has been confirmed). Systemic Lupus Erythematosus-Non-renal Key Inclusion/Exclusion Criteria Inclusion Criteria:
Positive for at least 1 of the following autoantibodies at Screening: anti- double stranded DNA or anti-Smith
Systemic Lupus Erythematosus Disease Activity Index-2000 score ≥ 8 AND at least 1 British Isles Lupus Assessment Group (BILAG)-2004 Class A (severe manifestation) organ scores
Inadequate response to glucocorticoids and to at least 2 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, or obinutuzumab Exclusion Criteria:
Subjects with neuropsychiatric SLE.
Drug-induced SLE. Systemic Lupus Erythematosus - Lupus Nephritis Key Inclusion/Exclusion Criteria Inclusion Criteria:
Positive for at least 1 of the following autoantibodies at Screening: anti- double stranded DNA or anti-Smith
Confirmed LN diagnosis by kidney biopsy during screening or within the previous 6 months, with severe active phase of the disease.
Progressing despite maintenance on maximally tolerated doses of renin- angiotensin system (RAS) blocking agents, unless allergic to or intolerant of ACE inhibitors and ARBs
Inadequate response to glucocorticoids and hydroxychloroquine and at least 1 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid derivatives, belimumab, azathioprine, methotrexate, rituximab, obinutuzumab, calcineurin inhibitor (cyclosporin, tacrolimus or voclosporin) Exclusion Criteria: •Evidence of Rapidly progressive glomerulonephritis (defined as a doubling of serum creatinine within 3 months prior to enrollment) or as determined by the study investigator. Systemic Sclerosis/Diffuse Cutaneous Systemic Sclerosis Cohort Key Inclusion/ Exclusion Criteria Inclusion Criteria:
Active disease defined as:
Modified Rodnan skin score (mRSS) ≥ 16 units, in the prior 6 months, with 1 or more of the following:
Increase in mRSS by ≥ 3 units or 10%
Involvement of 1 new body area with increase in mRSS by ≥ 2 units
Involvement of 2 new body areas with increase by ≥ 1 mRSS unit OR
Progressive interstitial lung disease (ILD) defined as: \- Worsening of respiratory symptoms and an increased extent of fibrosis evaluated by high-resolution computed tomography
Lack of response to standard therapy (e.g., failure of ≥ 2 immunosuppressive therapies) Exclusion Criteria:
"Active" gastric antral vascular ectasia, as evidenced by bleeding (ie, on esophagogastroduodenoscopy) in the past 6 months or as per Investigator's assessment.
History of SSc renal crisis within 1 year prior to Screening; presence of kidney impairment due to conditions other than SSc

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Milwaukee?

Yes, this clinical trial (NCT06708845) has an active research site in Milwaukee, WI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lupus Nephritis Treatment Options in Milwaukee, WI

If you're searching for lupus nephritis treatment options in Milwaukee, WI, this clinical trial (NCT06708845) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Milwaukee research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced lupus nephritis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lupus nephritis clinical trials near you to find additional studies recruiting in your area.

More Lupus Trials in Milwaukee, WI

See all lupus clinical trials recruiting in Milwaukee — not just this study.

Browse Lupus Trials in Milwaukee →

Browse More Trials by Condition

Lupus TrialsPulmonary Hypertension TrialsSystemic Lupus Erythematosus TrialsLupus Nephritis TrialsAll Conditions →

Ready to Join in Milwaukee?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Milwaukee, WI